The EPS projection of ImmunoGen, Inc. (NASDAQ:IMGN) for quarter ended 2016-09-30 is $-0.4. Last week, the EPS forecast was $-0.4 against target of $-0.4, a month earlier. Two months ago, this estimate was $-0.4 versus forecast of $-0.4 three months earlier, implying a deviation of 0%.
ImmunoGen, Inc. (NASDAQ:IMGN) stated that 18 days ago, its stock price was positively revised 0 times while negative revisions were 0.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 0, 0, and 0, correspondingly.
EPS estimate downgrade for ImmunoGen, Inc. (NASDAQ:IMGN) in the preceding 30, 120, 60 and 90 days were 0, 0, 0, and 0, correspondingly.
ImmunoGen, Inc. (NASDAQ:IMGN) EPS target for the quarter closed 3 was $-0.4, based on 5 recommendations. As reported on 2016-04-29 the EPS was $-0.37. The change was $-0.07, implying a percentage deviation of -23.33%. The projections showed a standard deviation of 0.04.
Quarterly Sales Estimates
ImmunoGen, Inc. (NASDAQ:IMGN) yearly sales prediction for the fiscal 2016 stands at $16.86 and the median estimate is at $16.68. Almost 3 analysts issued sales target.
Highest sales target is $17.8 while the lowest target is $16.1 showing standard deviation of 0.864%.
As many as 3 analysts have sales targets revised upside while 3 reduced sales estimates, implying a deviation of 0%.
Last month, 3 revised sales number projection on upside while 3 lowered the sales projections, implying a deviation of 0%.
A quarter ago, 3 hiked sales target and 3 reduced sales forecast. ImmunoGen, Inc. (NASDAQ:IMGN) announced that the deviation in forecast was -11.127%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...